LifeMD, Inc. (NASDAQ:LFMDP) Short Interest Update

LifeMD, Inc. (NASDAQ:LFMDP) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 6,200 shares, a growth of 148.0% from the March 31st total of 2,500 shares. Based on an average daily volume of 6,100 shares, the days-to-cover ratio is currently 1.0 days.

LifeMD Stock Up 1.2 %

Shares of NASDAQ LFMDP traded up $0.29 during midday trading on Monday, reaching $24.05. 1,375 shares of the stock were exchanged, compared to its average volume of 3,482. LifeMD has a twelve month low of $20.25 and a twelve month high of $27.44. The company has a 50 day simple moving average of $23.60 and a 200 day simple moving average of $22.79.

LifeMD Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, April 4th were paid a $0.5547 dividend. This represents a $2.22 annualized dividend and a dividend yield of 9.22%. The ex-dividend date of this dividend was Friday, April 4th.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.